Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;142(1):48-53.
doi: 10.1016/j.jaci.2018.05.005. Epub 2018 May 24.

New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting

Jonathan M Spergel  1 , Seema S Aceves  2 , Kara Kliewer  3 , Nirmala Gonsalves  4 , Mirna Chehade  5 , Joshua B Wechsler  6 , Marion Groetch  5 , Joshua Friedlander  7 , Evan S Dellon  8 , Wendy Book  9 , Ikuo Hirano  4 , Amanda B Muir  10 , Antonella Cianferoni  1 , Lisa Spencer  11 , Chris A Liacouras  10 , Edaire Cheng  12 , Leah Kottyan  13 , Ting Wen  3 , Thomas Platts-Mills  14 , Marc E Rothenberg  15
Affiliations

New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting

Jonathan M Spergel et al. J Allergy Clin Immunol. 2018 Jul.

Abstract

The Consortium of Eosinophilic Gastrointestinal Diseases and the International Gastrointestinal Eosinophil Researchers organized a day-long symposium at the recent 2018 Annual Meeting of the American Academy of Allergy, Asthma & Immunology, which was coupled for the first time with the World Allergy Organization meeting to create an international platform. The symposium featured experts in many facets of eosinophilic gastrointestinal diseases, including allergy, immunology, gastroenterology, pathology, and nutrition, and was a well-attended event. The basic science, genetics, cellular immunology, and clinical features of the diseases, with a focus on epithelial, eosinophil, and mast cell responses, as well as current and emerging treatment options, were reviewed. Here we briefly review some of the highlights of the material presented at the meeting.

Keywords: Eosinophilic esophagitis; diagnosis; food allergy; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: J. M. Spergel reports grants from the National Institutes of Health (NIH), End Allergy Together, and Aimmune Therapeutics; grants and personal fees from Regeneron, Shire, and DBV Technology; personal fees from UpToDate, Abbott, and the Annals of Allergy Asthma and Immunology outside the submitted work. S. S. Aceves reports a grant from the NIH and a UCSD patented licensed to Shire Pharma. M. Chehade reports receiving grants from NIH, PCORI, Nutricia, Regeneron, and Shire and consulting fees from Allakos and Shire. M. Groetch has received honoraria from Abbott, Nutricia North America and Mead Johnson for educational lectures. J. Friedlander reports personal fees and other from Triple Endos-copy and grants from the CURED Foundation, OEDIT-STATE of Colorado; in addition, J. Friedlander has a patent on Pediatric Nasal Endoscope/Aerodigestive Scope with royalties paid to University of Colorado. E. S. Dellon reports grants and personal fees from Adare, Banner, Celgene/Receptos, Regeneron, and Shire and personal fees from Alivio, Allakos, AstraZeneca, Enumeral, Robarts Clinical Trials; grants from Meritage, Miraca, Nutricia, and Holoclara. I. Hirano reports grants and consultant fees from Adare, Shire, Regeneron, and Receptos. A. Cianferoni reports grants and personal fees from DBV and grants from Shire. E. Cheng reports personal fees from Abbott Nutrition. L. Kottyan reports a pending patent WO2015142739A1. T. Wen and M. E. Rothenberg are co-inventors of issued and pending patents owned by CCHMC. M. E. Rothenberg reports grants from the NIH, a US-Israel Binational Grant, and PCORI; personal fees from Celgene and Genentech; equity in Immune Pharmaceuticals, PulmOne, and Spoon Guru; and personal fees from GlaxoSmithKline, Merck, Allakos, AstraZeneca, Celgene, and Regeneron; in addition, M. E. Rothenberg receives royalties from UpToDate and reslizumab (Teva Pharmaceuticals). The rest of the authors declare that they have no relevant conflicts to disclose.

References

    1. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr 2016;62:36–42. - PMC - PubMed
    1. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology 2018;154:319–32.e3. - PMC - PubMed
    1. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol 2014; 12:589–96.e1. - PMC - PubMed
    1. Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol 2015;110:626–32. - PMC - PubMed
    1. Jensen ET, Dellon ES. Environmental and infectious factors in eosinophilic esophagitis. Best Pract Res Gastroenterol 2015;29:721–9. - PMC - PubMed

Publication types

Supplementary concepts